Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
Study Information
Alliance Study ID: NCCTG-N0543
NCT Study ID (ClinicalTrials.gov): NCT00433550
Alliance Committee: Gastrointestinal Cancer
Disease or Cancer Type: Gastrointestinal Cancers – Pancreatic / Gastric / Esophageal / Liver / Biliary
Alliance Study Chair: Robert McWilliams, MD
Status: COMPLETED
Study Description
This phase II trial studies how well giving irinotecan hydrochloride together with oxaliplatin and capecitabine works as first-line therapy in treating patients with metastatic or unresectable locally advanced small bowel cancer. Drugs used in chemotherapy, such as irinotecan hydrochloride, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information